Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

TG Therapeutics develops treatments for B-cell diseases, with a primary focus on multiple sclerosis. Its lead product, Briumvi, serves as the cornerstone of its commercial success. Briumvi ...

Matthew Kaplan; Analyst; Ladenburg Thalmann & Co. Inc Mayank Mamtani; Analyst; B. Riley Securities ...

TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www ...

Factors that may affect TG Therapeutics operations include various ... This conference call is being recorded for audio rebroadcast on TG's website www.tgtherapeutics.com, where it will be ...